Merck says EU CHMP backs Keytruda-Padcev perioperative use in muscle-invasive bladder cancer

Bitget2026/09/18 10:55

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

EU CHMP backed Keytruda with Padcev for perioperative use in resectable muscle-invasive bladder cancer; European Commission decision due in Q4 2026.
Recommendation follows Phase 3 KEYNOTE-B15, showing event-free survival hazard ratio 0.53; overall survival hazard ratio 0.65 versus chemotherapy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck & Co. Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202609180655BIZWIRE_USPR_____20260917_BW438970) on September 18, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Merck says EU CHMP backs Keytruda-Padcev perioperative use in muscle-invasive bladder cancer

You may also like

Crypto prices